Loading…
GSP Crop Science (GSPCROP)₹432.05−1.41%Pesticides & Agrochemicals
In the Jun 2026 quarter (consolidated), GSP Crop Science reported sales of ₹387 Cr, up 2.4% from Jun 2025, and net profit of ₹26.06 Cr, up 13.1% year on year. For the year to Mar 2026, sales were ₹1,521 Cr and net profit ₹95.27 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 277 | 309 | 378 | 468 | 270 | 403 | 387 |
| Expenses | 273 | 268 | 334 | 373 | 257 | 366 | 342 |
| Operating Profit | 2.99 | 39.85 | 41.88 | 92.75 | 12.95 | 35.86 | 42.88 |
| OPM % | 1.0% | 13.0% | 11.0% | 20.0% | 4.9% | 9.0% | 11.0% |
| Other Income | 0.99 | 7.99 | 2.99 | 0.99 | −2.99 | 8.99 | 7.99 |
| Interest | 7.99 | 7.99 | 7.99 | 8.99 | 9.99 | 9.98 | 6.99 |
| Depreciation | 5.98 | 6.99 | 6.98 | 6.98 | 7.98 | 7.98 | 8.97 |
| Profit before tax | −11.01 | 32.01 | 29.99 | 78.07 | −8.01 | 27.01 | 35.01 |
| Tax % | −43.1% | 31.9% | 23.9% | 24.9% | −22.1% | 28.0% | 24.9% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | −4.18 | −0.04 | 0.00 |
| Net Profit | −6.02 | 22.05 | 23.05 | 58.16 | −6.02 | 20.06 | 26.06 |
| EPS (Rs) | −1.48 | 5.80 | 6.01 | 15.19 | −1.37 | 4.39 | 5.66 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 906 | 1,079 | 1,193 | 1,205 | 1,155 | 1,290 | 1,521 | 1,528 |
| Expenses | 831 | 947 | 1,060 | 1,124 | 1,027 | 1,135 | 1,330 | 1,338 |
| Operating Profit | 71.75 | 129 | 129 | 78.79 | 124 | 149 | 184 | 184 |
| OPM % | 8.0% | 12.0% | 11.0% | 7.0% | 11.0% | 12.0% | 12.0% | 12.1% |
| Other Income | 3.99 | 10.98 | 13.98 | 5.99 | 11.99 | 13.98 | 8.99 | 14.98 |
| Interest | 24.98 | 17.99 | 23.98 | 36.98 | 33.97 | 30.98 | 36.94 | 35.95 |
| Depreciation | 17.94 | 17.95 | 19.95 | 20.94 | 19.96 | 22.95 | 29.91 | 31.91 |
| Profit before tax | 34.01 | 103 | 100 | 27.01 | 81.97 | 110 | 127 | 132 |
| Tax % | 35.9% | 33.9% | 25.0% | 20.9% | 25.9% | 25.9% | 26.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −3.01 | −4.22 |
| Net Profit | 21.06 | 68.21 | 76.27 | 22.06 | 61.12 | 82.18 | 95.27 | 98.26 |
| EPS (Rs) | 72.22 | 229.83 | 255.55 | 77.74 | 235.22 | 21.36 | 21.04 | 23.87 |
| Dividend payout % | 10.0% | 4.0% | 4.0% | 3.0% | 4.0% | 4.0% | 5.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 29.12 | 29.08 | 29.10 | 27.10 | 26.12 | 39.13 | 47.20 |
| Reserves | 303 | 367 | 441 | 337 | 345 | 412 | 727 |
| Borrowings | 169 | 139 | 321 | 325 | 236 | 298 | 263 |
| Other Liabilities | 243 | 385 | 468 | 446 | 376 | 493 | 515 |
| Total Liabilities | 744 | 921 | 1,260 | 1,136 | 984 | 1,242 | 1,552 |
| Fixed Assets | 160 | 161 | 167 | 170 | 178 | 215 | 229 |
| CWIP | 6.98 | 8.98 | 10.98 | 15.95 | 50.88 | 49.91 | 66.83 |
| Investments | 2.01 | 0.00 | 1.99 | 3.01 | 8.01 | 12.01 | 15.99 |
| Other Assets | 575 | 750 | 1,080 | 949 | 748 | 965 | 1,241 |
| Inventories | 210 | 299 | 377 | 351 | 226 | 369 | 355 |
| Trade receivables | 281 | 291 | 406 | 414 | 323 | 396 | 552 |
| Cash & equivalents | 23.99 | 69.01 | 132 | 42.96 | 39.99 | 31.98 | 172 |
| Total Assets | 744 | 921 | 1,260 | 1,136 | 984 | 1,242 | 1,552 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 80.27 | 114 | −44.14 | 104 | 208 | 38.16 | 59.25 |
| Cash from investing activity | −23.98 | −19.01 | −41.95 | −46.98 | −18.99 | −79.90 | −73.89 |
| Cash from financing activity | −59.02 | −50.01 | 157 | −159 | −178 | 30.01 | 152 |
| Net cash flow | −3.01 | 45.07 | 71.10 | −102 | 10.01 | −12.03 | 137 |
| Capex | 15.94 | 22.93 | 49.81 | 33.89 | 28.89 | 72.79 | 76.69 |
| Free cash flow | 64.19 | 91.22 | −93.18 | 70.15 | 180 | −34.07 | −17.05 |
| CFO / OP % | 132.1% | 112.1% | −22.9% | 169.1% | 180.1% | 45.1% | 56.1% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 113 | 99 | 125 | 126 | 103 | 112 | 133 |
| Inventory days | 118 | 152 | 181 | 154 | 110 | 188 | 145 |
| Days payable | 113 | 162 | 165 | 156 | 114 | 176 | 158 |
| Cash conversion cycle | 119 | 89 | 141 | 124 | 98 | 125 | 120 |
| Working capital days | 55 | 52 | 73 | 57 | 40 | 51 | 69 |
| ROCE % | — | 23.0% | 18.1% | 8.0% | 17.0% | 21.0% | 19.1% |
For the Jun 2026 quarter, GSP Crop Science reported sales of ₹387 Cr, up 2.4% year on year and net profit of ₹26.06 Cr, up 13.1% year on year. The operating margin was 11.0%.
GSP Crop Science's sales for the year to Mar 2026 were ₹1,521 Cr; over the last twelve months they were ₹1,528 Cr.
Net profit for the year to Mar 2026 was ₹95.27 Cr, and ₹98.26 Cr over the last twelve months. Earnings per share over the same trailing period were ₹23.87.
GSP Crop Science reported borrowings of ₹263 Cr at Mar 2026, against cash and equivalents of ₹172 Cr.
Cash from operations was ₹59.25 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹17.05 Cr.